Exviera

dasabuvir

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Exviera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Exviera.

For practical information about using Exviera, patients should read the package leaflet or contact their doctor or pharmacist.

: Exviera is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of the liver caused by the hepatitis C virus.
It contains the active substance dasabuvir.

: Exviera can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in managing patients with chronic hepatitis C.
Exviera is available as 250 mg tablets, and the recommended dose is two tablets a day, one in the morning and one in the evening for 8, 12 or 24 weeks.
Exviera is always used in combination with another medicine, Viekirax, which contains the active substances ombitasvir, paritaprevir and ritonavir. Some patients taking Exviera are also treated with another antiviral medicine, ribavirin, in addition to Viekirax.
Several varieties (genotypes) of hepatitis C virus exist and Exviera is recommended for use in patients with virus of genotypes 1a and 1b. The combination of medicines used and the duration of treatment will depend on which genotype of hepatitis C virus the patient is infected with, the nature of the liver problems they have (for example, if they have liver cirrhosis (scarring) or their liver is not working properly) and whether they have received previous treatment. For further information, see the package leaflet.

: The active substance in Exviera, dasabuvir, works by blocking the action of an enzyme in the hepatitis C virus called ‘NS5B RNA-dependent polymerase’, which the virus needs to multiply. This stops the hepatitis C virus from multiplying and infecting new cells.

: In 6 initial main studies involving around 2,300 patients infected with hepatitis C virus genotypes 1a or 1b, Exviera in combination with Viekirax was effective in clearing the virus from the blood. Between 96% and 100% of patients without liver scarring had their blood cleared of the virus after 12 weeks of treatment (with or without ribavirin).
In patients with liver scarring, Exviera treatment in combination with Viekirax and ribavirin resulted in a clearance rate of between 93% and 100% after 24 weeks of treatment. In a seventh study, patients with liver scarring but stable liver function (compensated cirrhosis) who had genotype 1b infection were treated with Exviera and Viekirax without ribavirin and 100% of patients (60 out of 60 patients) had their blood cleared of the virus.

: The most common side effects with Exviera when used with Viekirax and ribavirin (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), nausea, pruritus (itching), asthenia (weakness) and fatigue (tiredness). For the full list of all side effects, see the package leaflet.
Exviera must not be used in women taking ethinylestradiol, an oestrogen found in hormonal contraceptives. It must also not be used together with medicines that affect the activity of certain enzymes that can raise or lower the level of the active substance in the blood. For the full list of restrictions, see the package leaflet.

: The European Medicines Agency noted that Exviera used in combination with Viekirax is effective in clearing the hepatitis C virus genotypes 1a and 1b from the blood with and without ribavirin. Almost all the patients in the studies had the virus cleared from their blood after 12 or 24 weeks. The clearance rate was particularly high in patients infected with genotype 1b.
Regarding its safety, although there were some cases of raised liver enzymes in patients treated with Exviera in combination with Viekirax and ribavirin, side effects seen with this combination were generally well tolerated. The Agency therefore concluded that the benefits of Exviera outweigh its risks and recommended that it be approved for use in the EU.

: The company that markets Exviera will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Exviera. This study is being carried out in light of data suggesting that patients treated with these medicines who have had liver cancer could be at risk of their cancer returning early.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Exviera have also been included in the summary of product characteristics and the package leaflet.

: The European Commission granted a marketing authorisation valid throughout the European Union for Exviera on 15 January 2015.
For more information about treatment with Exviera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

List item

Exviera : EPAR - Summary for the public (PDF/77.26 KB)

First published: 12/02/2015
Last updated: 08/02/2018
- Bulgarian
  (PDF/104.01 KB)
- Croatian
  (PDF/96.98 KB)
- Czech
  (PDF/102.13 KB)
- Danish
  (PDF/75.15 KB)
- Dutch
  (PDF/75.66 KB)
- Estonian
  (PDF/74.57 KB)
- Finnish
  (PDF/75.36 KB)
- French
  (PDF/76.29 KB)
- German
  (PDF/77.43 KB)
- Greek
  (PDF/105.77 KB)
- Hungarian
  (PDF/96.14 KB)
- Italian
  (PDF/75.56 KB)
- Latvian
  (PDF/100.2 KB)
- Lithuanian
  (PDF/100.26 KB)
- Maltese
  (PDF/105.3 KB)
- Polish
  (PDF/102.65 KB)
- Portuguese
  (PDF/76.01 KB)
- Romanian
  (PDF/98.56 KB)
- Slovak
  (PDF/100.72 KB)
- Slovenian
  (PDF/95.13 KB)
- Spanish
  (PDF/75.91 KB)
- Swedish
  (PDF/75.61 KB)
List item

Exviera : EPAR - Risk-management-plan summary (PDF/89.17 KB)

First published: 12/02/2015
Last updated: 12/04/2023

This EPAR was last updated on 13/04/2023

Authorisation details

Product details
Name	Exviera
Agency product number	EMEA/H/C/003837
Active substance	dasabuvir sodium
International non-proprietary name (INN) or common name	dasabuvir
Therapeutic area (MeSH)	Hepatitis C, Chronic
Anatomical therapeutic chemical (ATC) code	J05AP09
Accelerated assessment	This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Publication details
Marketing-authorisation holder	AbbVie Ltd
Revision	26
Date of issue of marketing authorisation valid throughout the European Union	14/01/2015
Contact address	Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB United Kingdom

Product information

12/08/2022 Exviera - EMEA/H/C/003837 - C/WS2430

List item

Exviera : EPAR - Product Information (PDF/403.9 KB)

First published: 12/02/2015
Last updated: 12/08/2022
- Bulgarian
  (PDF/444.04 KB)
- Croatian
  (PDF/437.35 KB)
- Czech
  (PDF/433.14 KB)
- Danish
  (PDF/414.82 KB)
- Dutch
  (PDF/422.66 KB)
- Estonian
  (PDF/404.21 KB)
- Finnish
  (PDF/424.62 KB)
- French
  (PDF/394.26 KB)
- German
  (PDF/427.71 KB)
- Greek
  (PDF/494.54 KB)
- Hungarian
  (PDF/423.33 KB)
- Icelandic
  (PDF/435.54 KB)
- Italian
  (PDF/417.95 KB)
- Latvian
  (PDF/421.38 KB)
- Lithuanian
  (PDF/455.18 KB)
- Maltese
  (PDF/464.19 KB)
- Norwegian
  (PDF/408.71 KB)
- Polish
  (PDF/439.25 KB)
- Portuguese
  (PDF/390.9 KB)
- Romanian
  (PDF/479.81 KB)
- Slovak
  (PDF/435.13 KB)
- Slovenian
  (PDF/408.57 KB)
- Spanish
  (PDF/414.74 KB)
- Swedish
  (PDF/412.78 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Exviera : EPAR - All Authorised presentations (PDF/17.79 KB)

First published: 12/02/2015
Last updated: 12/02/2015
- Bulgarian
  (PDF/36.49 KB)
- Croatian
  (PDF/26.85 KB)
- Czech
  (PDF/34.64 KB)
- Danish
  (PDF/17.74 KB)
- Dutch
  (PDF/17.97 KB)
- Estonian
  (PDF/19.63 KB)
- Finnish
  (PDF/19.63 KB)
- French
  (PDF/19.72 KB)
- German
  (PDF/21.62 KB)
- Greek
  (PDF/34.83 KB)
- Hungarian
  (PDF/22.98 KB)
- Icelandic
  (PDF/16.36 KB)
- Italian
  (PDF/19.74 KB)
- Latvian
  (PDF/36.39 KB)
- Lithuanian
  (PDF/36.06 KB)
- Maltese
  (PDF/26.64 KB)
- Norwegian
  (PDF/20.3 KB)
- Polish
  (PDF/24.54 KB)
- Portuguese
  (PDF/19.64 KB)
- Romanian
  (PDF/32.19 KB)
- Slovak
  (PDF/24.97 KB)
- Slovenian
  (PDF/30.56 KB)
- Spanish
  (PDF/17.34 KB)
- Swedish
  (PDF/16.47 KB)

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

For hepatitis C virus (HCV) genotype specific activity.

Assessment history

Changes since initial authorisation of medicine

List item

Exviera : EPAR - Procedural steps taken and scientific information after authorisation (PDF/289.13 KB)

First published: 30/09/2015
Last updated: 12/04/2023
List item

Exviera : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/142.32 KB)

First published: 07/07/2022
List item

Exviera-H-C-3837-P46-0021 : EPAR - Assessment report (PDF/422.73 KB)

Adopted

First published: 01/09/2021
EMA/92477/2021
List item

Exviera-H-C-3837-P46-0019 : EPAR - Assessment report (PDF/1.58 MB)

Adopted

First published: 30/08/2021
EMA/CHMP/105448/2019
List item

Exviera-H-C-PSUSA-10363-201801 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation (PDF/68.03 KB)

First published: 12/12/2018
EMA/633869/2018
List item

Exviera-H-C-3837-A20-1438 : EPAR - Assessment report - Article 20 (PDF/339.32 KB)

First published: 13/03/2017
Last updated: 13/03/2017
EMA/103226/2017
List item

Exviera-H-C-3837-A20-0017 : EPAR - Scientific Conclusion (PDF/58.19 KB)

First published: 13/03/2017
Last updated: 13/03/2017
- Bulgarian
  (PDF/93.44 KB)
- Croatian
  (PDF/85.24 KB)
- Czech
  (PDF/87.91 KB)
- Danish
  (PDF/51.14 KB)
- Dutch
  (PDF/54.25 KB)
- Estonian
  (PDF/46.24 KB)
- Finnish
  (PDF/46.29 KB)
- French
  (PDF/47.28 KB)
- German
  (PDF/55.97 KB)
- Greek
  (PDF/96.6 KB)
- Hungarian
  (PDF/68.84 KB)
- Italian
  (PDF/55.98 KB)
- Latvian
  (PDF/92.19 KB)
- Lithuanian
  (PDF/88.28 KB)
- Maltese
  (PDF/94.49 KB)
- Polish
  (PDF/89.56 KB)
- Portuguese
  (PDF/55.47 KB)
- Romanian
  (PDF/89.43 KB)
- Slovak
  (PDF/80.24 KB)
- Slovenian
  (PDF/88.19 KB)
- Spanish
  (PDF/47.5 KB)
- Swedish
  (PDF/55.05 KB)
List item

Exviera-H-C-PSUSA-00010363-201507 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/67.76 KB)

First published: 02/05/2016
Last updated: 02/05/2016
EMA/289707/2016

Exviera

Table of contents

Overview

Exviera : EPAR - Summary for the public (PDF/77.26 KB)

Exviera : EPAR - Risk-management-plan summary (PDF/89.17 KB)

Authorisation details

Product information

Exviera : EPAR - Product Information (PDF/403.9 KB)

Exviera : EPAR - All Authorised presentations (PDF/17.79 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Exviera : EPAR - Procedural steps taken and scientific information after authorisation (PDF/289.13 KB)

Exviera : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/142.32 KB)

Exviera-H-C-3837-P46-0021 : EPAR - Assessment report (PDF/422.73 KB)

Exviera-H-C-3837-P46-0019 : EPAR - Assessment report (PDF/1.58 MB)

Exviera-H-C-PSUSA-10363-201801 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation (PDF/68.03 KB)

Exviera-H-C-3837-A20-1438 : EPAR - Assessment report - Article 20 (PDF/339.32 KB)

Exviera-H-C-3837-A20-0017 : EPAR - Scientific Conclusion (PDF/58.19 KB)

Exviera-H-C-PSUSA-00010363-201507 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/67.76 KB)

Initial marketing-authorisation documents

Exviera : EPAR - Public assessment report (PDF/2.22 MB)

CHMP summary of positive opinion for Exviera (PDF/104.6 KB)

News

Related content

How useful was this page?